Filtered By:
Cancer: Chronic Leukemia

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 96 results found since Jan 2013.

Abstract 5267: Comorbidity and cause of death in patients with chronic lymphocytic leukemia (CLL)
Conclusions. Despite the advanced age at CLL diagnosis, the frequent presence of comorbidities, and the indolent nature of the disease, CLL progression is the ultimate cause of death in 51% of newly diagnosed CLL patients, with an additional 26% dying of causes potentially related to CLL, such as infections and second cancers. The influence of comorbidities and other clinical factors at diagnosis (e.g. smoking, Charlson Comorbidity Index) on survival and ultimate cause of death are being abstracted, and will be presented at the meeting.Citation Format: Paolo Strati, Kari Chaffe, Sara Achenbach, Timothy Call, Neil Kay, Jame...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Strati, P., Chaffe, K., Achenbach, S., Call, T., Kay, N., Cerhan, J., Slager, S., Shanafelt, T. Tags: Clinical Research (Excluding Clinical Trials) Source Type: research

2016 Moon Shot for Cancer: Focus on Prevention
It is now 2016, and Americans hope for a brighter, healthier new year. Are Americans healthier today than they were last year or the year before? Will there be fewer people diagnosed with cancer? According to the American Cancer Society, it is projected that in 2016 there will be 1,685,210 new cancer cases and 595,690 deaths due to cancer. This is an increase over previous years. While it is true that the death rate for several cancers has decreased (due mostly to better screening and earlier diagnosis), it is also true that several cancers are on the rise, including cancers of the thyroid, liver, pancreas, kidney, small i...
Source: Healthy Living - The Huffington Post - February 1, 2016 Category: Consumer Health News Source Type: news

Off-Hour Admission and Mortality Risk for 28 Specific Diseases: A Systematic Review and Meta-Analysis of 251 Cohorts Epidemiology
Conclusions Off-hour admission is associated with increased mortality risk, and the associations varied substantially for different diseases. Specialists, nurses, as well as hospital administrators and health policymakers can take these findings into consideration to improve the quality and continuity of medical services.
Source: JAHA:Journal of the American Heart Association - March 17, 2016 Category: Cardiology Authors: Zhou, Y., Li, W., Herath, C., Xia, J., Hu, B., Song, F., Cao, S., Lu, Z. Tags: Epidemiology, Risk Factors, Health Services, Meta Analysis, Mortality/Survival Source Type: research

Daily low-dose aspirin may help combat cancer
Conclusion The systematic review looked at 47 studies and attempted to combine the results, looking for evidence of a beneficial effect of low-dose aspirin on risk of death in people already diagnosed with cancer. The few RCTs identified – the best-quality evidence – did not provide conclusive evidence that aspirin improves survival rates. The rest of the studies were observational in nature, so cannot prove that aspirin reduces the risk of death from cancer. The only significant results were for a 24% reduction in risk of death from colon cancer, and a possible 11% reduced risk of death from prostate cancer. However,...
Source: NHS News Feed - April 22, 2016 Category: Consumer Health News Tags: Cancer Medication Source Type: news

Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders
Source: British Journal of Haematology - September 8, 2016 Category: Hematology Authors: Stephen P. Mulligan, Christopher M. Ward, David Whalley, Sarah N. Hilmer Tags: Editorial Comment Source Type: research

Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study
Summary Atrial fibrillation (AF) occurs in 5–9% of patients treated with ibrutinib for chronic lymphocytic leukaemia (CLL); the clinical consequences and optimal management are unclear. We retrospectively studied 56 CLL patients who received ibrutinib and developed AF. Median time to onset was 3·8 months. AF was persistent in 35/56 (62%) cases despite treatment. Clinical consequences included: three episodes of severe cardiac failure (one fatal) and one stroke; eight non‐thrombocytopenic patients (14%) experienced severe bleeding adverse events. Altogether, ibrutinib was permanently discontinued in 26/56 cases (46%)....
Source: British Journal of Haematology - September 8, 2016 Category: Hematology Authors: Philip A. Thompson, Vincent L évy, Constantine S. Tam, Chadi Al Nawakil, François‐Xavier Goudot, Anne Quinquenel, Loic Ysebaert, Anne‐Sophie Michallet, Marie‐Sarah Dilhuydy, Eric Van Den Neste, Jehan Dupuis, Michael J. Keating, Christophe Meune, F Tags: Short Report Source Type: research

Stroke-like encephalopathy following high-dose intravenous methotrexate in an adolescent with osteosarcoma: a case report
ABSTRACT Chronic lymphocytic leukemia is characterized by clonal proliferation and progressive accumulation of B-cell lymphocytes that typically express CD19+, CD5+ and CD23+. The lymphocytes usually infiltrate the bone marrow, peripheral blood, lymph nodes, and spleen. The diagnosis is established by immunophenotyping circulating B-lymphocytes, and prognosis is defined by two staging systems (Rai and Binet) established by physical examination and blood counts, as well as by several biological and genetic markers. In this update, we present the recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia for th...
Source: Revista Brasileira de Hematologia e Hemoterapia - December 29, 2016 Category: Hematology Source Type: research

Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia
Opinion statementThe development of tyrosine kinase inhibitors (TKIs) dramatically changed the treatment landscape for many different cancers including chronic myeloid leukemia (CML). With the introduction of imatinib, the first TKI developed and approved to effectively treat CML, patient survival has increased dramatically and, in some cases, this fatal cancer can be managed as a chronic disease. Since the approval of imatinib in 2002, four additional TKIs have been developed to treat this disease including the second-generation TKIs nilotinib, dasatinib, and bosutinib and the third-generation TKI ponatinib. Despite their...
Source: Current Treatment Options in Cardiovascular Medicine - March 17, 2017 Category: Cardiology Source Type: research

Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.
Abstract We analyzed adverse events (AEs) in 201 chronic phase CML patients treated with nilotinib (n = 120) or dasatinib (n = 81) as first- or second-line therapy. The dasatinib group had significantly higher grade 3-4 AEs compared to the nilotinib group (22 vs. 54%, p < 0.001), and had more frequent dose reduction, interruption, and discontinuation (p < 0.001, p = 0.004, and p = 0.006, respectively). Of 59 patients who discontinued treatment, 47 (80%) discontinued treatment due to AEs; 50% of the AEs causing drug discontinuation were of grade 2 severity. Compared to the second-line setting, dis...
Source: International Journal of Hematology - April 4, 2017 Category: Hematology Authors: Suh KJ, Lee JY, Shin DY, Koh Y, Bang SM, Yoon SS, Park S, Kim I, Lee JO Tags: Int J Hematol Source Type: research

Intracranial stenting for nilotinib treatment-associated cerebrovascular stenosis in chronic myeloid leukemia.
Authors: Ozaki T, Nakamura H, Izutsu N, Masaie H, Ishikawa J, Kinoshita M Abstract One of the second-generation tyrosine kinase inhibitors (TKIs), nilotinib, is increasingly used for imatinib-resistant or intolerant chronic myeloid leukemia (CML). Nilotinib is considered well tolerated with few side effects including hyperglycemia, hyperbilirubinemia and elevated levels of pancreatic enzymes. However, there is growing evidence that nilotinib accelerates atherosclerosis and causes peripheral arterial occlusive disease such as stroke, transient ischemic attack (TIA) and cardiovascular diseases. Herein, we report a ca...
Source: Interventional Neuroradiology - June 8, 2017 Category: Radiology Tags: Interv Neuroradiol Source Type: research

Elevated Cardiovascular Disease Risk in Patients With Chronic Myelogenous Leukemia Seen in Community-based Oncology Practices in the United States
Conclusion The increased risk of CVD observed in this real-world analysis of CML patients underscores the importance of current NCCN® recommendations to consider CV risk when selecting TKIs. Teaser Guidelines recommend that comorbidities, including CVD, be considered when selecting TKIs for the treatment of CML. An increased risk of CVD and its risk factors in CML patients treated by community-based US oncologists was identified in a real-world analysis of an EMR database (N=1,639). These results underscore the importance of current NCCN® recommendations to consider CV risk when selecting TKIs.
Source: Clinical Lymphoma Myeloma and Leukemia - June 20, 2017 Category: Cancer & Oncology Source Type: research

Cardiovascular Events after Exposure to Nilotinib in Chronic Myeloid Leukemia: Long Term Follow up
Conclusion The incidence of CVEs and frequency of asymptomatic PAD in this population was low and CVEs were associated with cardiovascular risk factors. Aggressive risk factor modification and applying standard definitions for measuring cardiovascular outcomes, might have contributed to the result. Further prospective and adequately powered studies are needed to explore the effect of cardiovascular risk profile on CVEs in CML patients on Nilotinib. Teaser This study evaluated the incidence of cardiovascular events (CVEs) in 63 chronic myeloid leukemia (CML) patients after long term exposure to Nilotinib. By considering the...
Source: Clinical Lymphoma Myeloma and Leukemia - July 15, 2017 Category: Cancer & Oncology Source Type: research

Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up
Conclusion The incidence of CVEs and the frequency of asymptomatic PAD in this population was low, and CVEs were associated with cardiovascular risk factors. Aggressive risk factor modification and applying standard definitions for measuring cardiovascular outcomes might have contributed to the findings. Further prospective and adequately powered studies are needed to explore the effect of the cardiovascular risk profile on CVEs in CML patients taking nilotinib. Micro-Abstract The present study evaluated the incidence of cardiovascular events (CVEs) in 63 chronic myeloid leukemia (CML) patients after long-term exposure to ...
Source: Clinical Lymphoma Myeloma and Leukemia - August 11, 2017 Category: Cancer & Oncology Source Type: research

Investigating the Mechanisms of Methotrexate Neurotoxicity in Patients With Childhood Leukemia and Long-Term Survivors
Adverse neurological events are common (4-20%) during treatment for pediatric acute lymphoblastic leukaemia (ALL) and include seizures, stroke like syndrome and leukoencephalopathy. In addition, chronic neurotoxicity is emerging as a worrying late effect of treatment with long-term survivors experiencing decreased executive function, processing speed and memory function. Survivors are also at increased risk of experiencing learning difficulties, social withdrawal issues and inattention hyperactivity disorders.
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Victoria Forster, Jane Carr-Wilkinson, Deborah Tweddle, Sirintra Nakjang, Sanaa Choufani, Rosanna Weksberg, Frederik van Delft Source Type: research

Therapy-free remission in chronic myeloid leukemia: possible mechanism.
Authors: Gale RP, Hochhaus A Abstract Chronic myeloid leukemia (CML) can be cured using tyrosine kinase-inhibitors (TKIs) when cure is defined as achieving a life-expectancy similar or even better than sex- and age-matched persons without CML. Most deaths in persons with CML are now from non-leukemia-related causes including heart disease, diabetes other cancers and stroke. Contrary to expectation, 40-50 percent of persons with CML treated for a few years with TKIs and who achieve a deep molecular response can stop TKI-therapy without leukemia recurrence for several years, some possibly indefinitely. Consequently, ...
Source: Expert Review of Hematology - February 18, 2018 Category: Hematology Tags: Expert Rev Hematol Source Type: research